Kolexia
Malouf Gabriel
Oncologie médicale
Hus Site Icans
Strasbourg, France
261 Activités
1.8 K Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Tumeurs du rein Carcinome médullaire Translocation génétique Métastase tumorale Sarcomes Tumeurs de la prostate Récidive tumorale locale

Industries

MSD
20 collaboration(s)
Dernière en 2023
Ipsen
10 collaboration(s)
Dernière en 2023
Bayer
2 collaboration(s)
Dernière en 2023
AstraZeneca
2 collaboration(s)
Dernière en 2021

Dernières activités

Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors.
Nature communications   30 novembre 2023
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Cell reports. Medicine   14 novembre 2023
Racial Disparities in MiT Family Translocation Renal Cell Carcinoma.
The oncologist   08 novembre 2023
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Cancer research   05 septembre 2023
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
Nature communications   26 mai 2023
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
The oncologist   10 mai 2023
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research   04 avril 2023
Abstract 1342: Roles of mesenchymal-like tumour cells and myofibroblastic cancer-associated fibroblasts in progression and therapeutic response of clear-cell renal cell carcinoma
Proceedings: AACR Annual Meeting 2023   01 avril 2023
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
The oncologist   22 décembre 2022
Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study.
Critical reviews in oncology/hematology   29 novembre 2022